Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

This study has been completed.
Sponsor:
Collaborator:
Centocor, Inc.
Information provided by:
University of Arizona
ClinicalTrials.gov Identifier:
NCT00796809
First received: November 21, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted

November 21, 2008
November 21, 2008
October 2007
June 2008   (final data collection date for primary outcome measure)
Determine the incidence rate and calculate the risk of coccidioidomycosis in patients receiving various anti-TNF agents or other biologics, and patients not receiving these agents for their inflammatory arthritis [ Time Frame: one year ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
  • To calculate the incidence density of coccidioidomycosis cases in patients receiving each drug. [ Time Frame: One year ] [ Designated as safety issue: Yes ]
  • To compare number of disseminated cases of coccidioidomycosis in each group [ Time Frame: One year ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis
Risk of Coccidioidomycosis in Patients Receiving Anti-TNF and Other Biologic Agents for an Inflammatory Arthritis

The goal of the project is to study the risk of coccidioidomycosis (valley fever) in patients receiving anti-TNF and other biologic agents for inflammatory arthritis in Tucson, Arizona.

Retrospective chart review of all patients with an inflammatory arthritis seen at the University Rheumatology clinic since January 2000.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample

Patients with an inflammatory arthritis receiving care at our Rheumatology ambulatory clinic at the University of Arizona

  • Coccidioidomycosis
  • Rheumatoid Arthritis
Not Provided
  • Biologics
    Patients receiving TNF inhibitors or biologic agents
  • DMARD
    Patients receiving methotrexate without any biologic
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
598
October 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All active patients with an inflammatory arthritis seen at the University of Arizona from January 2000

Exclusion Criteria:

  • None
Both
Not Provided
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00796809
07-0930-04
Yes
Berchman AustinVaz, MD, University of Arizona
University of Arizona
Centocor, Inc.
Principal Investigator: Berchman A Vaz, MD, PhD University of Arizona
University of Arizona
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP